Trypsin-EDTA Solution For Cell Dissociation Market Report 2025

This trypsin-EDTA solution for cell dissociation market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The trypsin-EDTA solution for cell dissociation market size has grown strongly in recent years. It will grow from $1.21 billion in 2024 to $1.33 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to increasing demand for efficient cell dissociation, rapid expansion of the biopharmaceutical sector, rise in cancer research, growing demand for regenerative medicine and stem cell research, increase in the number of academic and research institutions.

The trypsin-EDTA solution for cell dissociation market size is expected to see strong growth in the next few years. It will grow to $1.87 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to increasing focus on personalized medicine and targeted therapies, growth in biopharmaceutical production, increase the use of Trypsin-EDTA solutions in cell culture processes, rise in funding and initiatives for cancer research, demand for high-quality cell dissociation reagents. Major trends in the forecast period include use of animal-free and recombinant trypsin solutions, automated and high-throughput cell culture systems, use of serum-free media and supplements in cell culture, development of 3D cell culture and organoid models, regulatory and quality compliance in biopharmaceutical and clinical research.

The growing prevalence of chronic diseases is expected to drive the expansion of the trypsin-EDTA solution market for cell dissociation. Chronic diseases, such as diabetes, heart disease, and chronic respiratory conditions, are long-term health issues that require ongoing management. Factors contributing to the rise in chronic diseases include aging populations, increased incidence of risk factors such as poor diet and lack of exercise, and advances in medical technology that enable longer detection and management. Trypsin-EDTA solution is used in research on chronic diseases to efficiently detach and harvest cells from tissues or cultures for further analysis or therapeutic purposes. For example, a report by the World Health Organization in February 2024 highlighted that approximately 20 million new cancer cases were reported in 2022, with 9.7 million deaths. The number of new cancer cases is expected to exceed 35 million by 2050, marking a 77% increase from 2022. Consequently, the rising prevalence of chronic diseases is driving growth in the trypsin-EDTA solution market for cell dissociation.

The increasing demand for personalized medicine is anticipated to fuel the growth of the Trypsin-EDTA solution for cell dissociation market in the coming years. Personalized medicine is an approach that tailors treatments and healthcare decisions to the unique characteristics, needs, and genetic profiles of individual patients. This rising demand is largely driven by advancements in genomics, targeted therapies, and the growing prevalence of chronic diseases that necessitate more precise treatment strategies. Trypsin-EDTA solution for cell dissociation is important for personalized medicine as it facilitates efficient cell culture and manipulation, which are crucial for research and development in cell-based therapies and regenerative medicine. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based non-profit organization, reported that the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, a significant increase from six approvals in 2022. Among the newly approved treatments for 2023 were seven cancer drugs and three for other diseases and conditions. Consequently, the rising demand for personalized medicine is propelling the growth of the Trypsin-EDTA solution for cell dissociation market.

Leading companies in the trypsin-EDTA solution market are introducing innovative products, such as animal-based extracellular matrix (ECM) dissociation solutions, to gain a competitive advantage. These solutions are enzymatic or chemical formulations derived from animal sources that break down ECM components to facilitate cell detachment from tissue or culture surfaces. For instance, TheWell Bioscience, a US-based biomedical technology company, launched the VitroGel Organoid Recovery Solution in February 2023. This solution significantly improves the recovery process by enabling rapid and efficient detachment of organoids from both animal-based ECM and synthetic VitroGel hydrogels. It completes the dissociation of animal-based ECM in just 2 minutes, with the entire cell harvesting process taking only 15 minutes - much faster than the leading solution, which requires over 60 minutes. Designed to ensure high-quality and intact organoid recovery, the VitroGel solution enhances yield, cell viability, and quality for subsequent use. It operates at room temperature, eliminating the need for heat or cooling equipment and supporting full lab automation for high-throughput organoid production.

Major companies operating in the trypsin-edta solution for cell dissociation market are Thermo Fisher Scientific Inc., Merck KGaA, GE Healthcare, Corning Incorporated, Lonza Group AG, VWR International LLC, Sartorius AG, STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, MP Biomedicals LLC, American Type Culture Collection (ATCC), Cyagen Biosciences Inc., HiMedia Laboratories Private Limited, FUJIFILM Irvine Scientific Inc., Nacalai Tesque Inc., Creative Dynamics Inc., PromoCell GmbH, Biological Industries Israel Beit Haemek Ltd., Worthington Biochemical Corporation, Capricorn Scientific GmbH, PAN-Biotech GmbH, Cell Applications Inc., Innovative Cell Technologies Inc., Wisent Bioproducts Inc., ZenBio Inc.

North America was the largest region in the trypsin-EDTA solution for cell dissociation market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the trypsin-edta solution for cell dissociation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the trypsin-edta solution for cell dissociation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Trypsin-EDTA solution is a cell dissociation reagent that combines trypsin, an enzyme that breaks down proteins, with EDTA, a chelating agent that binds calcium ions. This combination helps detach adherent cells from the surfaces of culture vessels for further processing or analysis. It is used to effectively break down proteins and disrupt cell adhesion, facilitating the detachment and harvesting of cells.

The main types of trypsin-EDTA solutions for cell dissociation are 0.25% and 0.05% solutions. A 0.25% trypsin-EDTA solution consists of 0.25% trypsin and EDTA and is commonly used in cell culture to detach adherent cells by breaking down proteins responsible for cell adhesion. This solution can be distributed through various channels, including online sales, direct sales, and retail. It is used in applications such as insulin manufacturing, vaccine production, cell culture, and more.

The trypsin-EDTA solution for cell dissociation market research report is one of a series of new reports that provides trypsin-EDTA solution for cell dissociation market statistics, including trypsin-EDTA solution for cell dissociation industry global market size, regional shares, competitors with a trypsin-EDTA solution for cell dissociation market share, detailed trypsin-EDTA solution for cell dissociation market segments, market trends and opportunities, and any further data you may need to thrive in the trypsin-EDTA solution for cell dissociation industry. This trypsin-EDTA solution for cell dissociation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The trypsin-EDTA solution for cell dissociation market consists of sales of buffered trypsin-EDTA solution, trypsin-free cell dissociation solutions, enzyme-free cell dissociation solutions and trypsin- EDTA solutions with phenol red. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.